Tecentriq Disappoints In Post-Surgery Bladder Cancer
Fails To Hit Disease-Free Survival
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.